<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0010">
 <label>TABLE 21.1</label>
 <caption>
  <p>Prevention and Treatment of Respiratory Viral Infections for Pediatric Hematopoietic Cell Transplant Recipients, Solid Organ Transplant Recipients, and Oncology Patients</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Virus</th>
    <th>Prophylaxis</th>
    <th>Asymptomatic Shedding</th>
    <th>Upper Respiratory Tract Infection</th>
    <th>Lower Respiratory Tract Infection</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>RSV</td>
    <td>
     <list list-type="simple" id="l9800">
      <list-item id="u0010">
       <label>•</label>
       <p id="p0010">Infection control procedures</p>
      </list-item>
      <list-item id="u0015">
       <label>•</label>
       <p id="p0015">Palivizumab for children ≤2 years (during season) undergoing HCT</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9801">
      <list-item id="u0020">
       <label>•</label>
       <p id="p0020">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9802">
      <list-item id="u0025">
       <label>•</label>
       <p id="p0025">Isolation</p>
      </list-item>
      <list-item id="u0030">
       <label>•</label>
       <p id="p0030">HCT and Oncology: Ribavirin for high-risk situations
        <xref rid="tfn0015" ref-type="table-fn">a</xref>
        <sup>,</sup>
        <xref rid="tfn0020" ref-type="table-fn">b</xref>
        <sup>,</sup>
        <xref rid="tfn0025" ref-type="table-fn">c</xref>
       </p>
      </list-item>
      <list-item id="u0035">
       <label>•</label>
       <p id="p0035">SOT: limited data; consider oral ribavirin in lung transplant</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9803">
      <list-item id="u0040">
       <label>•</label>
       <p id="p0040">Isolation</p>
      </list-item>
      <list-item id="u0045">
       <label>•</label>
       <p id="p0045">Low-risk situations in HCT and oncology: consider oral ribavirin
        <xref rid="tfn0020" ref-type="table-fn">b</xref>
       </p>
      </list-item>
      <list-item id="u0050">
       <label>•</label>
       <p id="p0050">High-risk situations in HCT and oncology: consider aerosolized ribavirin initially followed by oral
        <xref rid="tfn0020" ref-type="table-fn">b</xref>
        <sup>,</sup>
        <xref rid="tfn0025" ref-type="table-fn">c</xref>
       </p>
      </list-item>
      <list-item id="u0055">
       <label>•</label>
       <p id="p0055">SOT: consider oral or aerosolized ribavirin in lung transplant</p>
      </list-item>
      <list-item id="u0060">
       <label>•</label>
       <p id="p0060">Supportive care</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Influenza A/B</td>
    <td>
     <list list-type="simple" id="l9804">
      <list-item id="u0065">
       <label>•</label>
       <p id="p0065">Infection control procedures</p>
      </list-item>
      <list-item id="u0070">
       <label>•</label>
       <p id="p0070">Vaccination of contacts</p>
      </list-item>
      <list-item id="u0075">
       <label>•</label>
       <p id="p0075">Vaccination 2-3 weeks before HCT in non-immunodeficient recipients of nonmyeloablative conditioning</p>
      </list-item>
      <list-item id="u0080">
       <label>•</label>
       <p id="p0080">Vaccination of post-HCT recipients: starting 6 months after transplant or starting 4 months after transplant during a community outbreak</p>
      </list-item>
      <list-item id="u0085">
       <label>•</label>
       <p id="p0085">Vaccination of SOT recipients: 2 months after transplant, earlier if outbreak; guidelines may change</p>
      </list-item>
      <list-item id="u0090">
       <label>•</label>
       <p id="p0090">Vaccination of oncology patients: no vaccination in patients receiving intensive chemotherapy or those who have received anti−B-cell antibodies in the past 6 months</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9805">
      <list-item id="u0095">
       <label>•</label>
       <p id="p0095">Isolation</p>
      </list-item>
      <list-item id="u0100">
       <label>•</label>
       <p id="p0100">Oseltamivir or zanamivir</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9806">
      <list-item id="u0105">
       <label>•</label>
       <p id="p0105">Isolation</p>
      </list-item>
      <list-item id="u0110">
       <label>•</label>
       <p id="p0110">Oseltamivir or zanamivir</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9807">
      <list-item id="u0115">
       <label>•</label>
       <p id="p0115">Isolation</p>
      </list-item>
      <list-item id="u0120">
       <label>•</label>
       <p id="p0120">Oseltamivir or zanamivir</p>
      </list-item>
      <list-item id="u0125">
       <label>•</label>
       <p id="p0125">Consider combination therapy with baloxavir if ≥ 12 years, or rimantadine (only influenza A) and/or ribavirin</p>
      </list-item>
      <list-item id="u0130">
       <label>•</label>
       <p id="p0130">Consider IV peramivir if mechanically ventilated</p>
      </list-item>
      <list-item id="u0135">
       <label>•</label>
       <p id="p0135">Supportive care</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>PIV</td>
    <td>
     <list list-type="simple" id="l9808">
      <list-item id="u0140">
       <label>•</label>
       <p id="p0140">Infection control procedures</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9809">
      <list-item id="u0145">
       <label>•</label>
       <p id="p0145">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9810">
      <list-item id="u0150">
       <label>•</label>
       <p id="p0150">Isolation</p>
      </list-item>
      <list-item id="u0155">
       <label>•</label>
       <p id="p0155">Consider reduction of steroid dose</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9811">
      <list-item id="u0160">
       <label>•</label>
       <p id="p0160">Isolation</p>
      </list-item>
      <list-item id="u0165">
       <label>•</label>
       <p id="p0165">Supportive care</p>
      </list-item>
      <list-item id="u0170">
       <label>•</label>
       <p id="p0170">Consider ribavirin if mechanically ventilated
        <xref rid="tfn0020" ref-type="table-fn">b</xref>
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>HMPV</td>
    <td>
     <list list-type="simple" id="l9812">
      <list-item id="u0175">
       <label>•</label>
       <p id="p0175">Infection control procedures</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9813">
      <list-item id="u0180">
       <label>•</label>
       <p id="p0180">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9814">
      <list-item id="u0185">
       <label>•</label>
       <p id="p0185">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9815">
      <list-item id="u0190">
       <label>•</label>
       <p id="p0190">Isolation</p>
      </list-item>
      <list-item id="u0195">
       <label>•</label>
       <p id="p0195">Supportive care</p>
      </list-item>
      <list-item id="u0200">
       <label>•</label>
       <p id="p0200">Consider ribavirin if mechanically ventilated
        <xref rid="tfn0020" ref-type="table-fn">b</xref>
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>HRV</td>
    <td>
     <list list-type="simple" id="l9816">
      <list-item id="u0205">
       <label>•</label>
       <p id="p0205">Infection control procedures</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9817">
      <list-item id="u0210">
       <label>•</label>
       <p id="p0210">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9818">
      <list-item id="u0215">
       <label>•</label>
       <p id="p0215">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9819">
      <list-item id="u0220">
       <label>•</label>
       <p id="p0220">Isolation</p>
      </list-item>
      <list-item id="u0225">
       <label>•</label>
       <p id="p0225">Supportive care</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>HCoV</td>
    <td>
     <list list-type="simple" id="l9820">
      <list-item id="u0230">
       <label>•</label>
       <p id="p0230">Infection control procedures</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9821">
      <list-item id="u0235">
       <label>•</label>
       <p id="p0235">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9822">
      <list-item id="u0240">
       <label>•</label>
       <p id="p0240">Isolation</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="l9823">
      <list-item id="u0245">
       <label>•</label>
       <p id="p0245">Isolation</p>
      </list-item>
      <list-item id="u0250">
       <label>•</label>
       <p id="p0250">Supportive care</p>
      </list-item>
     </list>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <italic>HCoV,</italic> human coronavirus; 
    <italic>HCT,</italic> hematopoietic cell transplant; 
    <italic>HMPV</italic>, human metapneumovirus; 
    <italic>HRV,</italic> human rhinovirus; 
    <italic>IV,</italic> intravenous; 
    <italic>PIV,</italic> parainfluenza virus; 
    <italic>RSV,</italic> respiratory syncytial virus; 
    <italic>SOT,</italic> solid organ transplant.
   </p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tfn0015">
   <label>a</label>
   <p id="np9100">Because of recent price increases, most centers have restrictions on the use of aerosolized ribavirin.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tfn0020">
   <label>b</label>
   <p id="np9102">Benefit and dosing of oral ribavirin not clearly understood.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tfn0025">
   <label>c</label>
   <p id="np9103">High risk: lymphopenia, smoking history, and use of high-dose total-body irradiation.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
